Related Experiment Video
Updated: Jun 12, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Castration-refractory prostate cancer: New drugs in the pipeline
Dirk Schrijvers1, Peter Van Erps, Jim Cortvriend
1Department of Hemato-Oncology, Ziekenhuisnetwerk Antwerpen-Middelheim, B-2020 Antwerp, Belgium. dirk.schrijvers@zna.be
Abstract:
The standard treatment for patients with castration-refractory prostate cancer (CRPC) is the combination docetaxel-prednisone, if the patient can support chemotherapy. Several new treatments have been tested in chemotherapy-naïve or docetaxel-pretreated patients with CRPC. Some of these treatments have shown activity in first-line and second-line treatment. In this review, an update is given of new treatment studies performed in patients with CRPC.
Related Concept Videos
Treatment Resistent Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers

